Current Topics in Behavioral Neurosciences
2022
Nathalie M Rieser, Marcus Herdener, Katrin H Preller
Substance use disorders (SUD) represent a significant public health issue with a high need for novel and efficacious treatment options. In light of this high unmet need, recent results reporting beneficial outcomes of psychedelic-assisted therapy in SUD are particularly relevant. However, several questions remain with regard to this treatment approach. The clinical mechanisms of action of...
Current Topics in Behavioral Neurosciences
2022
Matthew W. Johnson
31 citations
This manuscript reviews research suggesting that classic psychedelics (5-HT2A receptor agonists) are effective in treating addictions including tobacco use disorder. I review historical research from the 1950s to 1970s suggesting that classic psychedelics are associated with addiction recovery across pharmacologically distinct drugs of addiction. I then review anthropological reports about...
Current Topics in Medicinal Chemistry
December 2, 2021
Teresa Reynolds de Sousa, João Rema, Sérgio Machado et al.
7 citations
Background: The therapeutic options for neurobehavioral disorders are still limited, and in many cases, they lack a satisfactory balance between efficacy and side effects. Objective: This work aims to review current evidence regarding the potential contribution of psychedelics and hallucinogens to the discovery of new drugs for treating different psychiatric disorders. Discussion:...
Alcoholism & Drug Abuse Weekly
November 19, 2021
Gary Enos
With nicotine being one of the most addictive substances and the available treatments for nicotine addiction leading to no better than a 30% success rate, it's no wonder that a newly announced multisite study of the psychedelic psilocybin for smoking cessation is generating excitement. While taking care not to oversell the potential of this strategy, those involved with the research hope at...
Science Advances
November 17, 2021
Marcus W. Meinhardt, Simone Pfarr, Grégory Fouquet et al.
92 citations
Alcohol-induced mGluR2 deficits are restored by psilocybin, resulting in a rescue of pathological behaviors in alcoholism.
Canadian Medical Association Journal
November 14, 2021
Greg Basky
7 citations
Research interest in the therapeutic use of psilocybin, or "magic mushrooms," is growing alongside a "wild west" of dispensaries in Canada and the United States. The past decade has seen a revival of research exploring the clinical use of psychedelics in treating depression, addiction,
Sexual & Relationship Therapy
October 20, 2021
Dee Dee Goldpaugh
22 citations
During the last two decades, psychedelic-assisted therapy has emerged as one of the most promising novel treatments for depression, anxiety, PTSD, and substance use disorders. These medicines have also been used in sacred, ritual settings for, in some cases, centuries. Often referred to as entheogens (meaning “creating the divine within”), psychedelic plant medicines such as psilocybin...
Alcoholism & Drug Abuse Weekly
September 24, 2021
Alison Knopf
First it was the plant, cannabis. How could this be made into a saleable profit‐making commodity when it grows in the ground? Witness the marijuana (a chemical from the plant) industry, which lobbied to make sure laws in states that legalized it banned people from growing more than a few plants.
L'Encephale
August 1, 2021
Lucie Berkovitch, Bruno Romeo, Laurent Karila et al.
25 citations
Psychedelics are powerful psychoactive substances. Natural psychedelics have been used for millennia by human civilizations, in particular in Latin America, while synthetic psychedelics were discovered in the 50s, giving rise to a lot of research before they were prohibited. More recently, their therapeutic properties have been studied especially to help patients with psychiatric conditions,...
Preprints.org
June 28, 2021
Maurizio Coppola, Francesco Bevione, Raffaella Mondola
1 citation
preprint
Psychedelics extracted by plants have been used in religious, spiritual and mystic practices for millennia. In 1957, Dr. Hofmann have identified and synthesized the prodrug psilocybin, a substance present in more than 200 species of psychedelic mushrooms. Although the limitations related to the scientific design of many studies, clinical observations performed during the 1950s and the 1960s...